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(US$20,888). RESULTS: The total cost of six-months treatment with rivaroxaban 
was US$89 and US$96* higher than warfarin. Increased drug cost (US$356) 
associated with rivaroxaban, was offset by reduced monitoring costs (US$239). 
Moreover, rivaroxaban was associated with LY increments of 0.006 and 0.026* 
years and QALY increments of 0.005 and 0.022* years. The ICERs were US$16,227 
and US$3,488* per LY gained and US$17,928 and US$4,056* per QALY gained. 
Sensitivity analysis showed that ICER value was sensitive only to the frequency 
of monitoring (between two to six-times a year) in warfarin patients. 
CONCLUSIONS: Rivaoxaban is cost-effective in the Turkish setting for the acute 
treatment of DVT patients, with ICERs below accepted WTP threshold across a 
range of conservative scenarios. * all pairs of figures correspond to 5-years and life-
time horizon, respectively.  
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OBJECTIVES: To build a flexible pharmacoeconomic model for early-stage 
analysis of interventions to prevent major adverse cardiovascular events 
(MACE=non fatal myocardial infarction (MI) and stroke, and cardiovascular 
death). METHODS: A literature search of cost-effectiveness models of 
cardiovascular disease interventions was conducted. Two models, one for heart 
disease and one for stroke, were selected as the framework (e.g., health states 
and transitions) for the development of an acute coronary syndrome (ACS) 
microsimulation model. Major parameter inputs were extracted from published 
literature. UK-based exploratory analyses using health state costs from the 
National Health System (NHS) reference costs and drug costs from the NHS 
October 2012 Electronic Drug Tariff, varied first-year risk of subsequent MACE 
events from 8-12%; and treatment efficacy (defined as a relative risk reduction 
(RRR)) from 15-25%. The base case treatment comparator was defined as 
standard of care (SoC) consistent with guidelines on secondary prevention of MI, 
including antihypertensive medications, aspirin, a statin, and one year of 
clopidogrel after each ACS event. New treatments can be added to, or substituted 
in the SoC. Age, gender, and patient history were varied for 10,000 individual 
patients simulated over specified timeframes. RESULTS: The model estimates a 
range of 15 to 39 MACE avoided per thousand patients in one year for a 15% RRR 
with an 8% background MACE rate versus a 25% RRR with a 12% background 
MACE rate, respectively. Assuming a £20,000/QALY willingness to pay in the UK, 
estimated lifetime incremental costs and QALYs predict the net benefit to be 
£1,371 for a point estimate of 20% RRR of a 10% background MACE rate. 
CONCLUSIONS: Early cost-effectiveness analyses using feasible RRRs in typical 
background MACE rates seen in ACS populations can be cost effective. Validation 
of this model framework can lead to more robust conclusions.  
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OBJECTIVES: Venous thromboembolism (VTE) causes significant impact on 
morbidity/mortality and economic burden to health systems. For preventing VTE 
in hip fracture/arthroplasty, the American College of Chest Physicians Practice 
Guidelines recommends the use of antithrombotic agents, such as fondaparinux 
and low-molecular weight heparin (LMWH). We present a cost-effectiveness 
analysis of fondaparinux versus enoxaparin for the prevention of VTE in hip 
surgery in Brazil. METHODS: A decision model was developed with a 180-day 
post-surgery horizon for the comparison of fondaparinux versus enoxaparin, 
both administered during hospitalization (average eight days) for the prophylaxis 
of VTE in hip surgery. Thromboembolic event and major bleeding probabilities 
were derived from three major published randomized clinical trials comparing 
fondaparinux and enoxaparin (N>6,000). Costs were calculated using 
microcosting technique in search for hip surgery and thrombotic/hemorrhagic 
complications reimbursed from the public Brazilian Unified Health System 
Database (DATASUS) in June 2012. Drug prices for antithrombotic prophylaxis 
were extracted from the Health Prices Database (BPS) in 2012 (1BRZ=0.52USD). 
RESULTS: VTE was observed in 5.9% versus 11.5% of patients with fondaparinux 
and enoxaparin, respectively (relative risk reduction=48.8%). Major bleeding 
(leading to death, reoperation or in critical sites) were similar in both groups, 
although bleeding with index >2 were more frequent in fondaparinux (2.4% 
versus 1.7%). Cost-effectiveness data showed fondaparinux was dominant over 
enoxaparin (i.e., reduced mortality at lower costs). There was an increment of 
three deaths per 1,000 patients by using enoxaparin instead of fondaparinux. 
Fondaparinux reported cost savings of BRZ16.53 per patient treated. Influence 
analysis showed that the incremental deaths and costs of enoxaparin were 
largely related to the higher incidence of thrombotic complications. 
CONCLUSIONS: Fondaparinux was found to be a cost-effective option under the 
Brazilian Public Health System perspective for the prophylaxis of VTE, resulting 
in lower mortality incidence at a reduced budget impact.  
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OBJECTIVES: In the management of atrial fibrillation (AF), warfarin has been the 
anticoagulant of choice for preventing thrombotic complications, however, its 
need for regular blood test monitoring has led to the development of alternatives 
such as dabigatran. In order to address the variability and uncertainties in cost-
effectiveness and budget impact across jurisdictions, a systematic review of 
economic analyses was conducted. METHODS: A systematic review was 
conducted of economic evaluations published to November 2011 evaluating the 
cost-effectiveness of dabigatran versus warfarin for stroke prevention in AF. 
Databases searched included Ovid MEDLINE, EMBASE, the Cochrane Library and 
PubMed. The grey literature was also searched for relevant articles. For the 
purpose of a qualitative synthesis, details on the study design, data sources, cost 
effectiveness results (i.e. incremental cost effectiveness ratios (ICER)) were 
abstracted. Key factors influencing the cost-effectiveness of dabigatran 
compared with warfarin across different countries and health systems were 
identified. RESULTS: Seven economic evaluations comparing dabigatran and 
warfarin from four countries were identified. Costs, QALYs and ICERS were 
reported in all but one study. ICERs for dabigatran compared to warfarin ranged 
from £4,879.17 to $152,142.86 US, depending on the dabigatran dose and 
currency. Variations in ICERs occurred despite the fact that the efficacy and 
hemorrhage data were obtained from the same source, the RE-LY trial. Key 
factors identified between the models for variability in the results included 
differences in the costs of managing AF across countries; assumptions regarding 
warfarin monitoring frequency and costs, and INR control (trial-like or real-world 
setting); incorporation of baseline risk in relative rates of adverse events; and the 
costs of treating dabigatran-related hemorrhages without an antidote. 
CONCLUSIONS: Economic analyses for dabigatran versus warfarin have 
produced widely varying results. Real world effectiveness and safety data, 
including warfarin management practices, are useful to inform cost-
effectiveness in practice.  
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OBJECTIVES: . Due to the aging of the population, musculoskeletal diseases, 
particularly articular diseases and fragility fractures, have been constantly 
increasing. For this reason, total hip replacement (THR) and total knee 
replacement (TKR) have also increased. These procedures impact the quality of 
life and imply high risk of venous thromboembolism (VeT). VeT events have a 
high mortality in the elderly, 21% on hospitalized patients and up to 39% one 
year after the surgery. Prophylaxis for VeT is as a major strategy to minimize the 
consequences on patients undergoing TKR and THR. The aim of this study was to 
assess the cost-effectiveness (CE) of apixaban against dabigatran, rivaroxaban, 
fondaparinux, and enoxaparin for VeT prevention on these patients in 
Guatemala, from the private health care perspective. METHODS: . A simulated 
cohort of 1,000 patients subjected to THR/TKR entered a decision-tree model to 
compare costs and effectiveness of apixaban (2.5 mg/12 hours), dabigatran (220 
mg/day), rivaroxaban (10 mg/day), fondaparinux (2.5 mg/day) and enoxaparin (30 
mg/12 hours). Effectiveness measures were: total VeT events, bleeding rates and 
deaths. The model used a 5 year time horizon and only direct medical costs were 
considered (inpatient costs, medication expenses, adverse events, tests). 
Effectiveness and epidemiologic data were retrieved from published literature. 
Local costs (2012 US$) were gathered from the 3 private hospitals of Guatemala 
official databases. RESULTS: . The total VeT events were 69 for Apixaban, 55 for 
Rivaroxaban, 112 for Dabigatran, 86 for Enoxaparin and 45 for Fondoparinux. The 
estimated bleeds were 71 (Apixaban), 85 (Rivaroxaban), 85 (Dabigatran), 73 
(Enoxaparin) and 31 (Fondaparinux). Apixaban dominated enoxaparin and 
dabigatran while rivaroxaban and fondaparinux had an ICER of 
US$104,177/QALY and US$103,933/QALY, respectively. In the acceptability 
curves, Apixaban appeared with the highest probability of being cost-effective. 
CONCLUSIONS: . Apixaban resulted as the cost-effective therapy for VeT 
prevention for adult patients in Costa Rica.  
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OBJECTIVES: Aortic stenosis is the most common valvular heart disease in the 
elderly - it is estimated that its prevalence is up to 5% in individuals over 75 
years. Its standard treatment is surgical valve replacement; however the surgical 
risk is very high for patients with advanced age and with the association of 
comorbidities. Thus, a significant proportion of patients become ineligible for 
this therapy. Treatment with transcatheter aortic valve implantation (TAVI) is a 
therapy with potentially lower risk peri-procedure and has been used as a 
therapeutic option in this group of patients considered inoperable. The aim of 
this study was to develop a cost-effectiveness analysis of the SAPIEN® valve 
implantation in patients with severe aortic stenosis who are not eligible for 
surgical treatment. METHODS: A Markov model was developed to compare the 
